# To Evaluate the Phase I Clinical Study of JSKN016 in Chinese Patients With Advanced Malignant Solid Tumors

Source: https://onco.cc/trials/nct06592417/  
OnCo record `nct06592417` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

An early trial studying the safety and activity of experimental treatment. Its registry status does not establish patient benefit.

## Summary

To Evaluate the Phase I Clinical Study of JSKN016 in Chinese Patients With Advanced Malignant Solid Tumors. ClinicalTrials.gov record last updated 2024-09-19: recruiting. Enrollment is planned at 140 participants. Primary completion is estimated at 2026-05-17. No tabular results are posted on ClinicalTrials.gov; this does not exclude separate publications.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-10-06
- Registry id: NCT06592417
- Phase: 1
- Setting: To Evaluate the Phase I Clinical Study of JSKN016 in Chinese Patients With Advanced Malignant Solid Tumors
- Sponsor: Jiangsu Alphamab Biopharmaceuticals Co., Ltd

## Notes

- ClinicalTrials.gov record last updated 2024-09-19: recruiting. Enrollment is planned at 140 participants. Primary completion is estimated at 2026-05-17. No tabular results are posted on ClinicalTrials.gov; this does not exclude separate publications.

## Sources

- ClinicalTrials.gov NCT06592417: https://clinicaltrials.gov/study/NCT06592417

## Connected records

- targets: [TROP2](https://onco.cc/targets/trop2/)
- drugs: [JSKN016](https://onco.cc/drugs/jskn016/)

---
JSON: https://onco.cc/api/v1/entities/nct06592417.json